These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2521814)

  • 1. Immunomodulatory and therapeutic properties of FK-565 in mice.
    Talmadge JE; Lenz B; Schneider M; Phillips H; Long C
    Cancer Immunol Immunother; 1989; 28(2):93-100. PubMed ID: 2521814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481).
    Kurakata S; Tomatsu M; Arai M; Arai H; Hishinuma A; Kohno H; Kitamura K; Kobayashi T; Nomoto K
    Cancer Immunol Immunother; 1991; 33(2):71-9. PubMed ID: 1828007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Augmentation of natural killer (NK) cell activity in human blood lymphocytes by a new synthetic acyltripeptide (FK-565) and its derivatives].
    Shimizu E; Tandon P; Utsugi T; Sone S
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2353-7. PubMed ID: 3460529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).
    Wang BS; Ruszala-Mallon V; Wallace RE; Citarella RV; Lin YI; Durr FE
    Cancer Immunol Immunother; 1986; 22(1):8-14. PubMed ID: 2939949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
    Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Schlick E; Ruffmann R; Wiltrout RH; Chirigos MA
    Cancer Res; 1985 Mar; 45(3):1058-65. PubMed ID: 3155990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of effects of a heptanoyl tripeptide, FK-565, on porcine macrophage and lymphocyte function.
    Chitko CG; Chapes SK; Thaler RC; Nelssen JL; Anderson GA; Clough ER; Blecha F
    Am J Vet Res; 1991 Jan; 52(1):169-73. PubMed ID: 2021246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of tumoricidal properties in macrophages and inhibition of experimentally-induced murine metastases by a new synthetic acyltripeptide, FK-565.
    Inamura N; Nakahara K; Kino T; Gotoh T; Kawamura I; Aoki H; Imanaka H; Sone S
    J Biol Response Mod; 1985 Aug; 4(4):408-17. PubMed ID: 4031951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage involvement in the antitumor activity of a synthetic acyltripeptide (FK-565) against experimental lung carcinoma metastases.
    Schultz RM; Altom MG
    J Immunopharmacol; 1986; 8(4):515-28. PubMed ID: 3543138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoactive peptides, FK 156 and FK 565. IV. Activation of mouse macrophages.
    Watanabe Y; Tawara S; Mine Y; Kikuchi H
    J Antibiot (Tokyo); 1985 Dec; 38(12):1781-7. PubMed ID: 3005214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.
    Fukui H; Reynolds CW; Lenz B; Schneider M; Talmadge JE
    Cancer Immunol Immunother; 1989; 29(1):1-6. PubMed ID: 2784999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopotentiation by a new antitumor polysaccharide, DMG, a degraded D-manno-D-glucan from Microellobosporia grisea culture fluid.
    Nakajima H; Kita Y; Takashi T; Akasaki M; Yamaguchi F; Ozawa S; Tsukada W; Abe S; Mizuno D
    Gan; 1984 Mar; 75(3):260-8. PubMed ID: 6427053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of murine susceptibility to tumor, parasite and bacterial challenge with altered cell-mediated immunity following systemic exposure to the tumor promoter phorbol myristate acetate.
    Murray MJ; Lauer LD; Luster MI; Luebke RW; Adams DO; Dean JH
    Int J Immunopharmacol; 1985; 7(4):491-500. PubMed ID: 3876295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of synthetic acyltripeptide and its analogs with recombinant interferon gamma for activation of antitumor properties of human blood monocytes.
    Sone S; Okubo A; Inamura N; Nii A; Ogura T
    Cancer Immunol Immunother; 1988; 27(1):33-7. PubMed ID: 3135118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a new peptidyl-hypoxanthine derivative on natural killer cells and antitumor activity.
    Migliorati G; Cornaglia-Ferraris P; Cannarile L; Delfino D; D'Adamio F; Mosci F; Stradi R; Rossi E; Guidi G; Riccardi C
    Cancer Detect Prev; 1991; 15(4):319-22. PubMed ID: 1794138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages.
    Black PL; Phillips H; Tribble HR; Pennington R; Schneider M; Talmadge JE
    Cancer Immunol Immunother; 1993 Oct; 37(5):299-306. PubMed ID: 8402733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of cytotoxic responses by prostaglandin E2.
    Häcker-Shahin B; Dröge W
    Cell Immunol; 1985 Mar; 91(1):43-51. PubMed ID: 3871666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
    Nagarkatti M; Nagarkatti PS; Kaplan AM
    Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
    Basu S; Sodhi A; Singh SM; Suresh A
    Immunol Lett; 1991 Mar; 27(3):199-204. PubMed ID: 2060971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five).
    Talmadge JE; Benedict KL; Uithoven KA; Lenz BF
    Immunopharmacology; 1984 Feb; 7(1):17-26. PubMed ID: 6232241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.